IL263619A - Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof - Google Patents

Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

Info

Publication number
IL263619A
IL263619A IL263619A IL26361918A IL263619A IL 263619 A IL263619 A IL 263619A IL 263619 A IL263619 A IL 263619A IL 26361918 A IL26361918 A IL 26361918A IL 263619 A IL263619 A IL 263619A
Authority
IL
Israel
Prior art keywords
indol
pyrimidin
acrylamide
dimethylamino
ethoxy
Prior art date
Application number
IL263619A
Other languages
Hebrew (he)
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of IL263619A publication Critical patent/IL263619A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL263619A 2016-06-17 2018-12-10 Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof IL263619A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351749P 2016-06-17 2016-06-17
PCT/US2017/037872 WO2017218892A1 (en) 2016-06-17 2017-06-16 Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

Publications (1)

Publication Number Publication Date
IL263619A true IL263619A (en) 2019-01-31

Family

ID=60664309

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263619A IL263619A (en) 2016-06-17 2018-12-10 Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

Country Status (17)

Country Link
US (1) US10844045B2 (en)
EP (1) EP3471730B1 (en)
JP (1) JP6928964B2 (en)
KR (1) KR20190018494A (en)
CN (1) CN109937043A (en)
AU (1) AU2017285448B2 (en)
BR (1) BR112018075823A2 (en)
CA (1) CA3027732A1 (en)
CO (1) CO2018013416A2 (en)
EA (1) EA201892661A1 (en)
IL (1) IL263619A (en)
MX (1) MX2018015508A (en)
PH (1) PH12018502668A1 (en)
SG (1) SG11201810976TA (en)
TW (1) TW201800404A (en)
WO (1) WO2017218892A1 (en)
ZA (1) ZA201808234B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018232235A1 (en) 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN110898026A (en) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 Pharmaceutical composition containing BPI-7711 and preparation method thereof
CN111100117B (en) * 2019-12-18 2021-02-19 上海倍而达药业有限公司 Crystal form A of aminopyrimidine compound mesylate and preparation method and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3333161T (en) * 2011-07-27 2020-05-11 Astrazeneca Ab 2- (2,4,5-SUBSTITUTED-ANILINE) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USED IN THE TREATMENT OF CANCER
DE102011115849B3 (en) 2011-10-13 2012-05-10 Thomas Magnete Gmbh Metering pump for use as electromagnetically driven reciprocating pump in e.g. truck, has metallic mold in damper whose bias is adjusted by rotation of socket relative to outlet or by rotation of atomization device relative to socket
HRP20190407T1 (en) 2014-06-19 2019-05-03 Ariad Pharmaceuticals, Inc. HETEROaryl Compounds for Inhibition of Kinases
CN105315285B (en) * 2014-07-25 2017-12-08 上海海雁医药科技有限公司 2,4 2 substitution 7H pyrrolo-es [2,3 d] pyrimidine derivatives, its preparation method and purposes pharmaceutically
CN106458969A (en) * 2014-08-25 2017-02-22 四川海思科制药有限公司 A kind of (substituted phenyl)(substituted pyrimidine) amino derivative and its preparation method and pharmaceutical use
JP6456086B2 (en) * 2014-09-25 2019-01-23 キヤノン株式会社 Projection type image display apparatus and control method thereof, projector and control method thereof
CN111170998B (en) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 Pyrimidine or pyridine compound, preparation method and medical application thereof
MY183474A (en) 2014-12-10 2021-02-19 Oji Holdings Corp Absorbent article
EP3229798A4 (en) * 2014-12-11 2018-05-30 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as egfr modulators
CN104961731A (en) * 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 Phosphate of epidermal growth factor receptor inhibitor, and crystal form and preparation method thereof
CN104910049B (en) * 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 AZD9291 intermediate and preparation method thereof
BR112018072887A2 (en) 2016-05-11 2019-03-06 Beta Pharma, Inc. brain cancer treatment method in an individual, and use of a compound

Also Published As

Publication number Publication date
ZA201808234B (en) 2019-11-27
JP2019518062A (en) 2019-06-27
EP3471730B1 (en) 2021-10-20
CO2018013416A2 (en) 2019-01-18
KR20190018494A (en) 2019-02-22
AU2017285448B2 (en) 2021-02-04
WO2017218892A1 (en) 2017-12-21
EA201892661A1 (en) 2019-07-31
US20190233399A1 (en) 2019-08-01
TW201800404A (en) 2018-01-01
CN109937043A (en) 2019-06-25
US10844045B2 (en) 2020-11-24
CA3027732A1 (en) 2017-12-21
MX2018015508A (en) 2019-04-11
EP3471730A4 (en) 2019-11-27
EP3471730A1 (en) 2019-04-24
AU2017285448A1 (en) 2019-01-03
PH12018502668A1 (en) 2019-10-07
SG11201810976TA (en) 2019-01-30
BR112018075823A2 (en) 2019-03-26
JP6928964B2 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
FR24C1030I2 (en) N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE HYDROCHLORIDE SALTS
IL271220A (en) Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
HUE059624T2 (en) N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for cancer treatment
MA45937A (en) AMINO PYRIMIDINE SSAO INHIBITORS
IL244787B (en) Polymorph c of n-((4,6-dimethyl-2 oxo-1,2-dihydropyridine-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1 ,1' -biphenyl]-3-carboxamide monohydrochloride, methods of preparing it, pharmaceutical compositions comprising it and its use
HUE051693T2 (en) 5-Chloro-N4- [2- (dimethylphosphoryl) phenyl] -N2- {2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4 crystalline forms of diamine
DK3658547T3 (en) PROCESS FOR THE PREPARATION OF N-(5-(4-(4-FORMYL-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YLAMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE
LT3658552T (en) MANUFACTURE OF N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE METHOD FOR CARRYING OUT THE REACTION BETWEEN THE CORRESPONDING AMINE AND 3-HALOGEN-PROPIONYL CHLORIDE
EP3263553A4 (en) Crystalline modification of n-(2-(3-phenylureido)phenyl)benzenesulfonamide and recording material using same
IL263619A (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
BR112018013356A2 (en) hydrochloride salt, crystalline forms of a hydrochloride salt and pharmaceutical composition
EP3414225C0 (en) CRYSTALLINE MODIFICATIONS OF N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL)-GUANIDINE HYDROCHLORIDE AND N-(4,5-BISMETHANESULFONYL-2-METHYLBENZOYL)-GUANIDINE SALTS
EP3700889A4 (en) MALEAT SALTS OF E) -N- (3-CYANO-7-ETHOXY-4 - ((4-PHENOXYPHENYL) AMINO) QUINOLINE-6-YL) -4- (DIMETHYLAMINO) BUT-2-ENAMIDE AND CRYSTALLINE FORMS OF IT
HK1242181A1 (en) Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n’-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto
EA201890806A1 (en) P2X7 RECEPTOR INHIBITOR